Fluvastatin and fluvastatin extended release: a clinical and safety profile

References

• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 19,1434–1503 (1998).
   PubMedGoogle Scholar
• Tyroler HA. Coronary heart disease epidemiology in the 21st century. Epidemiology Rev. 22, 7–13 (2000).
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. MONitoring trends and determinants In CArdiovascular disease. Lancet 353, 1547–1557 (1999).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro 0, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16,434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. Br. Med. J. 303,276–282 (1991).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. 333,1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo—Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT—LLA): a multicenter, randomized controlled trial. Lancet 361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. J. Am. Med. Assoc. 287, 3215–3222 (2002).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events trial investigators. N Engl. J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellström B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 361,2024–2031 (2003).
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl. J. Med. 339,1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285,2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev. 11,121–146 (1991).
   PubMedGoogle Scholar
• Lilja JJ, Kivisni KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol Ther. 66,118–127 (1999).
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivisni KT, Neuvonen M, Laitila J, NeuvonenPJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Then 69,340–345 (2001).
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Then 68,122–129 (2000).
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Then 75, 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur. J. Clin. Pharmacol. 54,851–855 (1999).
   PubMed Web of Science ®Google Scholar
• Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 21,567–572 (1993).
   PubMed Web of Science ®Google Scholar
• Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: clinical implications and practical attempts to avoid potential problems. Heart Drug 4,55–79 (2004).
   Google Scholar
• Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36, 288–295 (2002).
   PubMed Web of Science ®Google Scholar
• Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 212, 628–635 (1981).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Kurokawa J, Nomura S, Kuga Y, Ohkura Y, Kajiyama G. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochem. Biophys. Acta 1167, 223–225 (1993).
   PubMedGoogle Scholar
• Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31, 348–371 (1996).
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21,1712–1719 (2001).
   PubMed Web of Science ®Google Scholar
• Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11,2295–2322 (1997).
   PubMed Web of Science ®Google Scholar
• Corsini A. Fluvastatin: effects beyond cholesterol lowering. J. Cardiovasc. Pharmacol. Then 5,161–175 (2000).
   PubMedGoogle Scholar
• Rikitake Y, Kawashima S, Takeshita S et al. Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154,87–96 (2001).
   PubMed Web of Science ®Google Scholar
• Yasuhara M, Suzumura K, Tanaka K et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol. Pharm. Bull. 23,570–574 (2000).
   PubMedGoogle Scholar
• Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 22, 692–698 (2002).
   PubMed Web of Science ®Google Scholar
• Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17, 1521–1526 (1997).
   Google Scholar
• Ito T, Ikeda U, Shimpo M et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc. Drugs Then 16,121–126 (2002).
   PubMed Web of Science ®Google Scholar
• Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 348,1584 (1996).
   PubMed Web of Science ®Google Scholar
• Hausberg M, Kosch M, Stam F et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 59,1473–1479 (2001).
   PubMed Web of Science ®Google Scholar
• Kosch M, Barenbrock M, Suwelack B, Schaefer RI\4, Rahn KH, Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibitor, fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am. J. Kidney Dis. 41,1088–1096 (2003).
   PubMed Web of Science ®Google Scholar
• Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin. Transplant. 17,385–390 (2003).
   PubMedGoogle Scholar
• Haak E, Abletshauser C, Weber S et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidemia. Atherosclerosis 155, 395–401 (2001).
   PubMed Web of Science ®Google Scholar
• Eichstädt HW, Abletshauser CB, Stork T, Weidinger G. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J. Cardiovasc. Pharmacol. 35,735–740 (2000).
   PubMedGoogle Scholar
• Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. 80, 278–286 (1997).
   PubMed Web of Science ®Google Scholar
• Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell. Physiol. 139,550–557 (1989).
   PubMed Web of Science ®Google Scholar
• Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb. Haemost. 90, 607–610 (2003).
   PubMedGoogle Scholar
• Katznelson S, Wilkinson AH, Kobashigawa JA et al. The effect of pravastatin on acute rejection after kidney transplantation — a pilot study. Transplantation 61,1469–1474 (1996).
   PubMed Web of Science ®Google Scholar
• Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a 4-year randomized trial. Circulation 96, 1398–1402 (1997).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N EngL J. Med. 333,621–627 (1995).
   PubMed Web of Science ®Google Scholar
• Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 60, 1990–1997 (2001).
   PubMed Web of Science ®Google Scholar
• Holdaas H, Jardine A. Acute renal allograft rejections, a role for statins? Minerva Ural. Nefrol. 55,111–119 (2003).
   PubMedGoogle Scholar
• Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63, 367–378 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 25,457–481 (2003).
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. Pharmacokinetic—pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41,343–370 (2002).
   PubMed Web of Science ®Google Scholar
• Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Then 80,1–34 (1998).
   PubMed Web of Science ®Google Scholar
• Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 32, 630–638 (1992).
   PubMed Web of Science ®Google Scholar
• Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)- fluvastatin. Clin. Pharmacol. Ther. 58,412–417 (1995).
   PubMed Web of Science ®Google Scholar
• Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. 37,502–511 (2001).
   PubMed Web of Science ®Google Scholar
• Tse FL, Smith HT, Ballard FH, Nicoletti J. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. Biopharm. Drug Divas. 11,519–531 (1990).
   PubMedGoogle Scholar
• Kivistn KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. 46, 49–53 (1998).
   PubMedGoogle Scholar
• Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am. J. Hypertens. 6, S375—S382 (1993).
   Google Scholar
• Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am. J. Cardiol. 76, A97—A101 (1995).
   Google Scholar
• Scripture CD, Pieper JA. Clinica l pharmacokinetics of fluvastatin. Clin. Pharmacoki net. 40,263–281 (2001).
   PubMed Web of Science ®Google Scholar
• Smit JW, Wijnne HJ, Schobben F, Sitsen A, de Bruin TW, Erkelens DW. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am. J. Cardiol. 76, A89—A96 (1995).
   Google Scholar
• Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27, 410–416 (1999).
   PubMed Web of Science ®Google Scholar
• Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann. Pharmacother. 30,1399–1402 (1996).
   PubMed Web of Science ®Google Scholar
• Jokubaitis LA. Fluvastatin in combination with other lipid-lowering agents. Br. J. Clin. Pract. Suppl. 77A, 28–32 (1996).
   PubMedGoogle Scholar
• Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74, 186–194 (2003).
   PubMed Web of Science ®Google Scholar
• Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56,225–229 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporin. Transplantation 62,1559–1564 (1996).
   PubMed Web of Science ®Google Scholar
• Park JW, Siekmeier R, Lattke P et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporin A. J. Cardiovasc. Pharmacol. Ther. 6, 351–361 (2001).
   PubMedGoogle Scholar
• Takeda M, Noshiro R, Onozato ML et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol. 483,133–138 (2004).
   PubMed Web of Science ®Google Scholar
• Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30,1352–1356 (2002).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30,505–512 (2002).
   PubMed Web of Science ®Google Scholar
• Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76, A80—A83 (1995).
   Web of Science ®Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301, 1042–1051 (2002).
   PubMed Web of Science ®Google Scholar
• Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am. J. Cardiol. 73, D18—D24 (1994).
   Web of Science ®Google Scholar
• Ballantyne CM, Pazzucconi F, Pinto X et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin. Ther. 23, 177–192 (2001).
   PubMed Web of Science ®Google Scholar
• Winkler K, Abletshauser C, Hoffmann MM et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with Type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. 87, 5485–5490 (2002).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Lievre M, Giral P et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am. J. Geriatr. Cardiol. 12,225–231 (2003).
   PubMedGoogle Scholar
• Riegger G, Abletshauser C, Ludwig M et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during 1 year of treatment. Atherosclerosis 144,263–270 (1999).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Foley DP, Jackson G et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the FLuvastatin Angiographic REstenosis (FLARE) trial. Eur. Heart J. 20,58–69 (1999).
   PubMed Web of Science ®Google Scholar
• Liem AH, van Boven AJ, Veeger NJ et al. Effect of fluvastatin on ischemia following acute myocardial infarction: a randomized trial. Eur. Heart J. 23, 193 1–1 937 (2002).
   Google Scholar
• Ballantyne CM, Herd JA, Ferlic LL et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99, 736–743 (1999).
   PubMed Web of Science ®Google Scholar
• SoRelle R. Baycol withdrawn from market. Circulation 104, E9015—E9016 (2001).
   Web of Science ®Google Scholar
• Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl. J. Med. 346,539–540 (2002).
   PubMed Web of Science ®Google Scholar
• Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch. Intern. Med. 160,2273–2280 (2000).
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 101, 207–213 (2000).
   PubMed Web of Science ®Google Scholar
• Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23,197–213 (2000).
   PubMed Web of Science ®Google Scholar
• Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am. J. Cardiol. 89,231–233 (2002).
   PubMed Web of Science ®Google Scholar
• Farnier M, Bortolini M, Salko T et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol 91,238–240 (2003).
   PubMed Web of Science ®Google Scholar
• Patel R, Paya CV Infections in solid-organ transplant recipients. Clin. Microbial Rev. 10, 86–124 (1997).
   PubMed Web of Science ®Google Scholar
• Green ML Evaluation and management of dyslipidemia in patients with HIV infection. J Gen. Intern. Med 17, 797–810 (2002).
   Google Scholar
• Ballantyne CM, Riegger G, Moore N, Saia F, Serruys PW. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc. Drugs Ther. 18,67–75 (2004).
   PubMed Web of Science ®Google Scholar
• Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J. Am. Soc. Nephrol 13, 1673–1681 (2002).
   PubMed Web of Science ®Google Scholar